We are live on ! Find out more

Baird Medical Investment Holdings

BDMD

Market cap $2.87M

0.0895 USD

+0.0015

1.7%

At close Updated Nov 9, 11:13 AM EST

1 day

1.7%

5 days

-14.84%

1 month

-88.38%

3 months

-92.66%

6 months

-94.67%

Year to date

-93.32%

1 year

-92.9%

5 years

-98.51%

10 years

-98.51%

About: Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China. The company combines clinical expertise with technologies to develop non-invasive treatment solutions. Its proprietary MWA medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Its core activities include the development and commercialization of thyroid microwave ablation systems and an active R&D pipeline of AI-integrated robotic systems, integrating hardware, software, and system-based solutions.

Employees: 146

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its strategic partner, Tianjin Yuanshan Medical Technology Co., Ltd. (“Alpmed”), has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) and an application for CE conformity assessment in the European Union for an irreversible electroporation (IRE) system.

Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System

Baird Medical Issues Statement Regarding Recent Share Price Volatility

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has provided the following statement regarding recent volatility in the market price of its ordinary shares. The Company is closely monitoring these fluctuations in the market price of its ordinary shares and the associated trading activity, and is not currently aware of any material development or otherwise undisclosed reason that would explain the recent decline in its ordinary share price.

Baird Medical Issues Statement Regarding Recent Share Price Volatility

Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company's shares, and Baird Medical's shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD.

Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

China Resources Medical Devices to serve as exclusive distributor for Baird's microwave ablation (MWA) products in 19 markets in the PRC Agreement includes initial purchase order of RMB 6 million ($900,000) NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its PRC subsidiary, Nanjing Changcheng Medical Equipment Company Limited, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. (“China Resources Medical Devices”), a subsidiary of China Resources Pharmaceutical Group Limited (Stock Code: 03320.HK).

Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion

Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.

Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C.

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

Revenue increase driven by significant growth in the United States and other strategic markets Revenue increase driven by significant growth in the United States and other strategic markets

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company's commercial activities in the country.

Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

See News Rankings

Price charts implemented using Lightweight Charts™